- 200, 400 and 600 mg tablets (PO)

- 100 mg/5 ml, 200 mg/5 ml suspension (PO)

- 600 mg/ 100 ml, 800 mg/8 ml vials (IV)

- 5% gel (topic)

Executive Summary

(September 29, 2023)

Ibuprofen is the most extensively studied NSAIDs for the treatment of acute pain and is prescribed worldwide in EDs for both pediatric and adult patients (21).

Adult dose for pain or fever (16, 17, 28)

400-800 mg IV or PO over 30 min every 6-8 hours as needed (maximum 3200 mg/day).

Adult dose

Adult dose for pain or fever (16, 28)

400-800 mg IV or PO over 30 min every 6-8 hours as needed (maximum 3200 mg/day).

Pediatric dose

Pediatric dose for pain or fever (22, 26, 28)

10 mg/kg/dose IV or PO every 6-8 hours as needed (maximum 40 mg/kg/day).


Ibuprofen analgesic ceiling

Unitary doses of 400 mg, and the cumulative daily dose of 1200 mg may be the analgesic ceiling of ibuprofen for acute pain conditions.

IV administration


Disadvantages: slow infusion


Pregnancy and lactation

Pregnancy risk classification
NSAID use in pregnant women at 30 weeks gestation and later may cause premature closure of the fetal ductus arteriosus (25). It has been warned by the US FDA that NSAID use at 20 weeks gestation or later may lead to fetal renal dysfunction (19)



® 2023 EMDrugs. All rights reserved.



This website provides general information and discussion about medications, health, and related subjects. The words and other con­tent pro­vided in this website, and in any linked mate­ri­als, are not intended and should not be con­strued as med­ical advice. If the reader or any other per­son has a med­ical con­cern, he or she should con­sult with an appropriately-licensed physi­cian or other legally accredited health care worker in the country that resides or is visiting. 


Please do not delay your medical concerns and potential health emergencies by searching information in this website, instead look out for medical opinion in the services that exist with that specific purpose and work under the respective local health-care regulations. 


The views expressed on this blog and web­site have no rela­tion to those of any academic, hospital, practice or other insti­tu­tion with which the authors are  affiliated. 


For other instances, the authors of this website do not have any conflict of interest with any institution or pharmaceutical company in particular, and do not receive any compensation about any licenced drug mentioned in the website. In the same matter, the website is not intended to recommend any specific patented medication.

EMDrugs Team